Glaukos price target raised to $120 from $107 at Citi

Citi raised the firm’s price target on Glaukos to $120 from $107 and keeps a Buy rating on the shares. Citi’s ophthalmologist survey indicates that while the first several quarters of iDose’s launch will likely be “gated” by reimbursement, training and patient selection interest is high and the numbers “can scale quickly,” the analyst tells investors in a research note. The firm says 70% of those surveyed plan to adopt iDose in once it is available.